INBS ships first readers from new partner Syrma Johari; expects 40%+ cost savings, 20ppt gross margin boost

INTELLIGENT BIO SOLUTIONS INC.

First Intelligent Fingerprinting Drug Screening Readers manufactured by Syrma Johari MedTech deployed to U.K. and Europe customers.
Partnership expected to deliver annual production cost savings over 40%, improving gross margin by ~20 percentage points annually.
In-house lateral flow test strip production capacity doubled, enabling faster R&D and expanded drug panels.
Company confirms planned U.S. market entry (beyond Forensic Use Only) later in 2026, supported by scaled manufacturing capacity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.